publication date: Jun. 13, 2014


CL40-24briefs.html

Kraft Named Director of University of Arizona Cancer Center

ANDREW KRAFT was named director of the University of Arizona Cancer Center and associate vice president for oncology programs for the University of Arizona Health Sciences Center.

Kraft will also serve as the Sydney E. Salmon endowed chair, as a tenured professor of medicine in the Division of Hematology/Oncology and as senior associate dean for translational research in the College of Medicine. He is scheduled to take the role of director in September.

He replaces Anne Cress, who has served as interim director of the cancer center since July 2013.

At UACC, Kraft will be responsible for the center’s $35 million research portfolio and oversight of oncology clinical operations in Tucson, in partnership with the University of Arizona Health Network. He also will oversee the development and implementation of the clinical and clinical research operations at the new UACC facility in Phoenix in collaboration with Dignity Health/St. Joseph’s Hospital and Medical Center, which is planned to be completed in summer 2015.

Previously, he served as associate dean for oncology affairs at the Medical University of South Carolina. Kraft led the Hollings Cancer Center’s efforts to become an NCI-designated cancer center in 2009.

At MUSC, he also served as a university distinguished professor of medicine and biochemistry and molecular biology, and held the William H. Folk, MD, Chair in Experimental Oncology.

Prior to his appointment at MUSC, Kraft was chief of the Division of Medical Oncology at the University … Continue reading 40-24 In Brief: Kraft Named Director of University of Arizona Cancer Center

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.